Asset profile
RAPA-201
Cell therapy
Evidence outlook · lead readout
NCT04176380 · Relapsed, Refractory Multiple Myeloma
The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.
NCT04176380: This was a small, single-arm, open-label study without randomization, blinding, or a comparator group. Its primary endpoint was overall response rate by IMWG criteria, but results were not posted, so there is no reported comparison or finding establishing benefit.
Also in development:Non-Small Cell Lung Cancer · Phase 1/2
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.